Department of Infectious Diseases, Kobe City Medical Centre General Hospital, Kobe, Japan.
Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Clin Microbiol Infect. 2018 Nov;24(11):1184-1189. doi: 10.1016/j.cmi.2018.01.021. Epub 2018 Mar 7.
To assess the effectiveness of short duration antimicrobial therapy for acute cholangitis with bacteraemia.
We conducted a retrospective cohort study of patients with acute bacteraemic cholangitis with successful biliary duct drainage at a single centre in Japan. We compared short-course antimicrobial therapy (SCT, ≤7 days) and long-course therapy (LCT, ≥8 days), with a primary outcome of 30-day mortality. We constructed logistic regression models for mortality and a composite outcome, including mortality, recurrence, recrudescence, new bacteraemia, liver abscess or other complications related to cholangitis. We also developed a propensity score for SCT with inverse probability weighting for both the primary outcome and the composite outcome.
We identified 263 patients in our cohort; 86 (32.7%) patients received SCT and the remaining 177 (67.3%) received LCT. The median durations of SCT and LCT were 6 days (range 2-7 days) and 12 days (range 8-46 days), respectively. The 30-day mortalities of SCT and LCT were 4.7% (4/85) and 5.7% (10/176), respectively (p 1.00). Logistic regression analysis showed that the odds ratio of SCT for 30-day mortality and the composite outcome were 1.07 (95% CI 0.25-4.52, p 0.93) and 1.08 (95% CI 0.48-2.45, p 0.85), respectively. Propensity score analyses for both 30-day mortality and the composite outcome did not demonstrate a difference between SCT and LCT (p 0.65 and p 0.95, respectively).
SCT with a median duration of 6 days did not have worse outcomes than LCT with a median duration of 12 days. Shortening the duration of antimicrobial therapy may be a reasonable option when treating acute bacteraemic cholangitis following successful biliary drainage.
评估短程抗菌治疗伴菌血症的急性胆管炎的疗效。
我们对日本一家中心成功胆道引流的急性菌血症性胆管炎患者进行了回顾性队列研究。我们比较了短程抗菌治疗(SCT,≤7 天)和长程治疗(LCT,≥8 天),主要结局为 30 天死亡率。我们为死亡率和包括死亡率、复发、再发、新发菌血症、肝脓肿或其他与胆管炎相关的并发症在内的复合结局构建了逻辑回归模型。我们还为 SCT 建立了倾向评分,对主要结局和复合结局均采用逆概率加权。
我们的队列中纳入了 263 例患者;86 例(32.7%)患者接受 SCT,其余 177 例(67.3%)患者接受 LCT。SCT 和 LCT 的中位疗程分别为 6 天(范围 2-7 天)和 12 天(范围 8-46 天)。SCT 和 LCT 的 30 天死亡率分别为 4.7%(4/85)和 5.7%(10/176)(p=1.00)。逻辑回归分析显示,SCT 治疗 30 天死亡率和复合结局的优势比分别为 1.07(95%CI 0.25-4.52,p=0.93)和 1.08(95%CI 0.48-2.45,p=0.85)。30 天死亡率和复合结局的倾向评分分析均未显示 SCT 和 LCT 之间存在差异(p=0.65 和 p=0.95)。
中位疗程 6 天的 SCT 与中位疗程 12 天的 LCT 相比,结局无差异。成功胆道引流后,急性菌血症性胆管炎的抗菌治疗疗程缩短可能是合理的选择。